We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Regeneron Pharmaceuticals Inc | NASDAQ:REGN | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 19.39 | 2.07% | 957.00 | 954.85 | 990.00 | 958.13 | 926.94 | 926.94 | 547,374 | 05:00:06 |
From May 2023 to May 2024
By Denny Jacob
Regeneron Pharmaceuticals said the Food and Drug Administration approved Veopoz to treat patients aged 1 year old and up who have CHAPLE disease.
The biotechnology company said the approval of Veopoz addresses pre-approval inspections issues related to the aflibercept 8 mg biologics license application. FDA action on the application is expected in the next few weeks, Regeneron said.
CHAPLE is a rare hereditary disease that can cause potentially life-threatening gastrointestinal and cardiovascular symptoms.
Regeneron said Veopoz would be the first treatment for adults and children with CHAPLE.
There are fewer than 10 patients with CHAPLE disease identified in the U.S., Regeneron said.
Write to Denny Jacob at denny.jacob@wsj.com
(END) Dow Jones Newswires
August 18, 2023 14:27 ET (18:27 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
1 Year Regeneron Pharmaceuticals Chart |
1 Month Regeneron Pharmaceuticals Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
